Unconjugated faecal bile acids in familial adenomatous polyposis analysed by gas-liquid chromatography and mass spectrometry
Barker, G. M., Radley, S., Davis, A., Imray, C. (Chris), Setchell, K. D. R., O'Connell, N., Donovan, I. A., Keighley, M. R. B. and Neoptolemos, J. P.. (1994) Unconjugated faecal bile acids in familial adenomatous polyposis analysed by gas-liquid chromatography and mass spectrometry. British Journal of Surgery, Vol.81 (No.5). pp. 739-742. ISSN 0007-1323Full text not available from this repository.
Official URL: http://dx.doi.org/10.1002/bjs.1800810541
Previous studies have suggested reduced formation of secondary bile acids in patients with familial adenomatous polyposis (FAP). Developments in the collection, extraction and analysis of faecal bile acids as well as in the accurate diagnosis of FAP by DNA markers prompted reinvestigation of this hypothesis. The median (interquartile range (i.q.r.)) faecal bile acid concentration (3·69 (1·66–5·36) μmol per g dry weight) and daily excretion rate (60·5 (29–149) μmol per g per 24 h) in ten patients with FAP were similar to those of nine control subjects (3·31 (0·65–8·38) μmol per g dry weight and 30·1 (7·9–228) μmol per g per 24 h). Although the median (i.q.r.) concentration of only one bile acid (12-oxo-lithocholic acid) was significantly different between patients with FAP and controls (49 (34–70) versus 0 (0–20) nmol per g dry weight, P=0·006), the derivatives of chenodeoxycholic acid (3·35 (1·76–5·32) versus 0·51 (0·13–2·37) μmol per g dry weight, P=0·02) and cholic acid (1·63 (0·42–2·34) versus 0·80 (0·13–3·57) μmol per g dry weight, P=0·006) were increased in those with polyposis. These results show increased bacterial biotransformation of faecal bile acids in patients with FAP.
|Item Type:||Journal Article|
|Divisions:||Faculty of Medicine > Warwick Medical School > Translational & Systems Medicine > Metabolic and Vascular Health
Faculty of Medicine > Warwick Medical School
|Journal or Publication Title:||British Journal of Surgery|
|Publisher:||John Wiley & Sons Ltd.|
|Page Range:||pp. 739-742|
|Access rights to Published version:||Restricted or Subscription Access|
Actions (login required)